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201 An evaluation of actual versus perceived use of the I-neb by 10
adult CF patients to assess potential beneﬁts of self monitoring
online tool on adherence to nebulised therapy recommendations
C.M. Williams1. 1Cheltenham Hospital, Physiotherapy Department,
Gloucestershire, United Kingdom
The I-neb Adaptive aerosol device (AAD) is used widely by CF patients.
The introduction of an online assessment tool facilitates patient self monitoring of
nebuliser efﬁciency, treatment times and breathing techniques.
Aim: To download and evaluate the use of the I-neb over a period of 1 year
by 10 patients; comparing this information with the patients perceived use of the
device to identify the potential beneﬁt of a patient self monitoring tool on treatment
concordance.
Method: I-neb data from a 12 month period was downloaded from 10 patients who
were issued with a short questionnaire asking them to outline how they had used
their nebuliser. The results were returned to the CF Physiotherapist and feedback
was compared with the downloaded data.
Results: 70% of patients perceived their I-neb use to be higher than the data down-
loaded (11.56% and 70.88%) 3 patients underestimated their use ((0.48%-1.5%).
Patients perceived that the I-neb provided a quick (80% estimated <5 mins) and
efﬁcient (80% estimated >75% dose delivery) method of drug delivery. The actual
% dose which the patients received ranged from between 94–100% (average 98.4%)
80% perceived that they received >75% each treatment. With 20% perceiving their
dose to be between 50 and 75%.
80% of patients expressed interest in the availability of a tool which provided
feedback on frequency of I-neb use, time taken, % dose delivered and quality of
the mesh of the device.
Conclusion: Patient interest in an online method of self assessment tool indicates
that this could be an effective method of improving concordance with treatment
recommendations and reducing the gap between perceived and actual I-neb usage.
202 Nebuliser strategies in cystic ﬁbrosis in Ireland. Results of a
national audit
D. Shortall1, M.J. Harrison1, C. Shortt1, M. McCarthy1, C. Fleming1,
D.M. Murphy1, P. Shanahan1, B. Plant1. 1Cork Adult Cystic Fibrosis Centre, Cork
University Hospital, Cork, Ireland
Objectives: Nebuliser therapy is a vital component of CF care. Recent advances
using mesh nebulisation (eFlow®) techniques offer improved delivery times for
patients compared to traditional jet nebulisers (Portaneb®, PARI BOY®). This audit
aims to examine current nebuliser strategies in Irish CF centres.
Methods: A nebuliser-use questionnaire was sent to 14 designated CF centres in
Ireland for completion by the senior CF physiotherapist.
Conclusions: 6 of 10 paediatric and 3 of 4 adult centres replied. All centres report
using Portaneb® nebulisers. eFlow® nebulisers were prescribed in 50% of paediatric
and adult centres, but only in centres where physiotherapists were responsible for
deciding nebuliser strategy. In the centres using eFlow®, 4 of 5 reported less than
25% of patients using an eFlow® device. Only one centre reported local health
authority/ industry funding to support the purchase of these devices. This centre
also had higher eFlow® use (50% of patients).
Traditional Portaneb® nebulisers are the mainstay of nebuliser therapy. Whilst newer
mesh technology devices were used in over half of Irish CF centres, the absolute
number using same was small. The reason for this low level of eFlow® usage is
beyond the remits of this study. However, centre preference, direct phyisotherapist
involvement and funding are possible contributory factors. Further studies are
required to determine the factors that inﬂuence this to allow the development of a
standardized national strategy.
203 A review of the use of hypertonic saline 7% during inpatient
treatment in paediatric cystic ﬁbrosis patients
C. Yonge1, S. Payne1, J. Legg1. 1Cystic Fibrosis Service, Child Health,
Southampton General Hospital, Southampton, United Kingdom
Background: The inhalation of hypertonic saline 7% (H.S.) has been shown to be
an effective mucolytic agent and a safe, low cost intervention for CF patients. In the
Southampton paediatric CF centre, we have altered our practise for the use of H.S.
during inpatient treatment. Since October 2010 all patients admitted for pulmonary
exacerbations are given H.S. pre airway clearance. All patients are treated with a
bronchodilator.
Method: A retrospective review was performed of the notes for all inpatients over
the past year. Any issues with tolerability of H.S. were recorded. Positive and
negative responses to H.S. were identiﬁed.
Results: All patients whilst in hospital received H.S. via a Pari LC plus to maximise
tolerance.
20 patients were reviewed with an age range of 18 mnths − 16 years.
19/20 had an increase in productive cough.
1/20 had no positive effect.
13/20 tolerated H.S. from the initial dose.
7/20 required further doses to achieve tolerance due to excessive cough. 4 of this
group had problems with excessive cough and nausea.
No children demonstrated bronchospasm even if previous evidence of bronchial
hyper reactivity.
8 patients continued to use H.S. at home.
Conclusion:We found a good level of acceptance of H.S. as an additional treatment
during in patient stays. Patients and parents expressed positive views about the
immediate effect of increased cough and sputum clearance, as this is uncommon
in most CF treatments. Excessive cough and nausea experienced by some patients
subsided with subsequent doses and enabled continuation of treatment. Interestingly
patients who have previously used H.S. retained their tolerability.
204 Complaining about time administration of colistimethate sodium
via I-Neb®: preliminary results
S. Gambazza1, D. Innocenti2, B. Ferrari2, S. Zuffo2. 1Azienda Ospedaliero-
Universitaria Meyer, Cystic Fibrosis, Firenze, Italy; 2Azienda Ospedaliero-
Universitaria Meyer, Rehabilitation Unit, Firenze, Italy
Background: Time requirements for multiple daily nebulizations may affect the
quality of life for the majority of patients with cystic ﬁbrosis (CF). The I-Neb®
Adaptive Aerosol Delivery (AAD) system can lead to shorter treatment times:
when operating in Tidal Breathing Mode (TBM), the AAD system calculates the
maximum ﬂow for each breath and how long the patient breathes in for. Since
I-Neb® was introduced in our CF centre, it happened that some patients complained
about long time requirements.
Aim:We therefore decided to preliminary investigate any relation between treatment
duration and some clinical parameters.
Methods: Patients were retrospectively recruited if compliance data were available
and only if they had already completed one cycle of therapy, to exclude poor
familiarity with the device. Sample was statistically described and preliminary
processed using Spearman correlation.
Results: 849 treatments were recorded, 100% in TBM mode. Mean administration
time was 4.58 minutes (min) (sd 1.97 range 1−17). 12.13% of treatments lasted
more than 7 min and 86.3% were inhaled by men. Patients’ (n = 10, 30% females)
mean age was 29.5 years (sd 9.4 range 16.7–48.6) with mean FEV1 1.38 L (sd 0.75
range 0.48–2.99), mean FVC 2.45 L (sd 1.05 range 0.54–3.85) and mean BMI
20 kg/m2 (sd 3.17 range 16.4–26.13). Patients spent on average 4.8 min (s.d 2.23)
ci [3.20; 6.40] to inhale the same drug. Statistically signiﬁcant lack of independence
between mean time of inhalation and BMI (ø= 0.72, d.f. 8 p = 0.01) was found.
Conclusions: Rigorous assumptions and larger sample size need to be considered
to further investigate the relationship between nebulization time and disease pro-
gression.
